STX vs. ELX, APC, STK, DGI, IDEA, VLG, DNL, EAH, PXS, and CHLL
Should you be buying Shield Therapeutics stock or one of its competitors? The main competitors of Shield Therapeutics include El Oro (ELX), Apc Technology Group (APC), StreaksAI (STK), DG Innovate (DGI), Ideagen (IDEA), Venture Life Group (VLG), Diurnal Group (DNL), ECO Animal Health Group (EAH), Provexis (PXS), and Chill Brands Group (CHLL).
Shield Therapeutics vs.
Shield Therapeutics (LON:STX) and El Oro (LON:ELX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking.
El Oro has lower revenue, but higher earnings than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than El Oro, indicating that it is currently the more affordable of the two stocks.
In the previous week, Shield Therapeutics had 1 more articles in the media than El Oro. MarketBeat recorded 1 mentions for Shield Therapeutics and 0 mentions for El Oro. El Oro's average media sentiment score of 0.00 beat Shield Therapeutics' score of -0.47 indicating that El Oro is being referred to more favorably in the news media.
11.9% of Shield Therapeutics shares are held by institutional investors. 62.2% of Shield Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
El Oro has a net margin of 0.00% compared to Shield Therapeutics' net margin of -173.43%. El Oro's return on equity of 0.00% beat Shield Therapeutics' return on equity.
Shield Therapeutics received 162 more outperform votes than El Oro when rated by MarketBeat users. Likewise, 75.17% of users gave Shield Therapeutics an outperform vote while only 59.55% of users gave El Oro an outperform vote.
Summary
Shield Therapeutics beats El Oro on 7 of the 12 factors compared between the two stocks.
Get Shield Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Shield Therapeutics Competitors List
Related Companies and Tools
This page (LON:STX) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy STX Stock Free STX Stock Alerts